TIPPERARY, Ireland, November 14, 2016 /PRNewswire/ -- Thei-plaqtest for Lp-PLA2is asimpleblood test whichmeasuresLipoprotein-Associated Phospholipase A2as an aidtoassessing risk of both coronary heart disease and ischemic strokeassociated with atherosclerosisi-plaq test represents entry into a large and growing new market segment for Technopath Clinical Diagnostics Technopath Clinical Diagnostics ("Technopath") today announced the launch of its first CE marked diagnostic reagent kit, the i-plaq test. TCD is an innovation driven privately owned invitro diagnostic company and the global leader in test-consolidated third party quality control materials with real time peer review software solutions. The i-plaq test for Lp-PLA 2 enables clinicians to quickly detect Lp-PLA 2, a vascular-specific inflammatory marker critical in the formation of rupture-prone plaque from a standard blood test. Higher levels of Lp-PLA 2 may indicate that the atherosclerotic plaque is more likely to rupture, leading to a dangerous blood clot that could result in cardiovascular disease (CVD) events. TCD expects that i-plaq's superior test performance and ease of use will significantly improve the CVD risk assessment for patients.